Annexon (ANNX) Share-based Compensation (2019 - 2026)
Annexon (ANNX) posted quarterly Share-based Compensation of $11.5 million for Q1 2026, up 126.47% year-over-year from $5.1 million in Q1 2025, and up 247.96% quarter-over-quarter from $3.3 million in Q4 2025.
Annexon (ANNX) Share-based Compensation (2019 - 2026) Analysis & Trends
Annexon's Share-based Compensation history runs 8 years deep, the most recent figure standing at $11.5 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 126.47% year-over-year to $11.5 million; the TTM figure through Mar 2026 stood at $11.5 million (down 42.07% YoY), while the FY2025 annual figure was $24.5 million, up 26.07% from the prior year.
- Share-based Compensation for Q1 2026 stood at $11.5 million, up from $3.3 million in the prior quarter.
- The five-year high for Share-based Compensation was $11.5 million in Q1 2026, with the low at $3.3 million in Q4 2025.
- The 5-year median for Share-based Compensation is $4.6 million (2024), against an average of $4.9 million.
- The sharpest annual moves came in 2025 and 2026: Share-based Compensation sank 36.71% in 2025, then jumped 126.47% in 2026.
- Annexon's Share-based Compensation stood at $4.8 million in 2022, then retreated by 9.64% to $4.4 million in 2023, then gained by 19.58% to $5.2 million in 2024, then tumbled by 36.71% to $3.3 million in 2025, then surged by 247.96% to $11.5 million in 2026.
- Business Quant data shows ANNX's Share-based Compensation at $11.5 million in Q1 2026, $3.3 million in Q4 2025, and $3.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - | 4.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.81 Mn |
| Jun 30, 2026 | 4.81 Mn |
| Mar 31, 2026 | 11.50 Mn |
| Mar 31, 2026 | 11.50 Mn |
| Dec 31, 2025 | 3.31 Mn |
| Dec 31, 2025 | 3.31 Mn |
| Sep 30, 2025 | 3.84 Mn |
| Sep 30, 2025 | 3.84 Mn |
| Jun 30, 2025 | 4.21 Mn |
| Jun 30, 2025 | 4.21 Mn |
| Mar 31, 2025 | 5.08 Mn |
| Mar 31, 2025 | 5.08 Mn |
| Dec 31, 2024 | 5.22 Mn |
| Dec 31, 2024 | 5.22 Mn |
| Sep 30, 2024 | 4.61 Mn |
| Sep 30, 2024 | 4.61 Mn |
| Jun 30, 2024 | 4.94 Mn |
| Jun 30, 2024 | 4.94 Mn |
| Mar 31, 2024 | 4.66 Mn |
| Mar 31, 2024 | 4.66 Mn |